BreakSight, Inc.

BreakSight, Inc. is a biotechnology company that provides a specialized service platform for identifying, mapping, and analyzing DNA double-strand break sites across the genome. Developed from research at the University of Pennsylvania, the company's technology, known as BrITL, involves tagging and retrieving DNA break ends from cells exposed to DNA-damaging treatments. The company offers two primary services: DDsite, which performs the capture and sequencing of these break sites, and DDinsight, which utilizes bioinformatics to identify reproducible break patterns, compare treatment conditions, and detect enriched DNA motifs or repeats. By uncovering defined, sequence-specific maps of DNA damage, BreakSight enables researchers to study genomic instability with high resolution.

This technology provides critical support to pharmaceutical and biopharmaceutical companies, as well as academic institutions, by helping them understand the mechanisms of action and resistance for targeted cancer therapeutics. By identifying novel DNA sequence biomarkers that predict therapeutic response, the company aims to expand the utility of genomic data beyond traditional gene-based mutations to the broader genome. This approach assists developers in optimizing drug combinations, assessing drug efficacy, and tailoring therapies to enhance precision medicine. BreakSight, based in Allentown, Pennsylvania, serves as a resource for researchers seeking to deepen their understanding of drug-induced DNA damage and improve outcomes in cancer research.